NEUROONE MEDICAL TECHNOLOGIES Corp
Close on Oct 19, 2026
- Market cap
- $8.74M
- P/E (TTM)
- –
- Dividend yield
- –
About Neuroone Medical Technologies
Surgical & Medical Instruments & Apparatus, SIC 3841
NeuroOne Medical Technologies Corporation is a medical technology company that develops thin-film electrode technologies for diagnostic, ablation, and stimulation applications. Its offerings target brain-related conditions, including epilepsy and Parkinson’s disease, as well as pain management and targeted drug delivery. The company’s commercialized devices include Evo Cortical and Evo sEEG electrodes for subsurface and brain-surface monitoring and stimulation, along with the OneRF Brain Ablation System and the OneRF TN Ablation System for nerve lesioning and chronic facial pain relief. It also actively designs combination devices for spinal cord stimulation, basivertebral nerve ablation, and preclinical therapeutic delivery. NeuroOne serves healthcare providers, including pain management physicians and surgeons, alongside commercial and biopharmaceutical partners such as Zimmer Biomet Holdings, Inc.
The company maintains its principal executive offices in Eden Prairie, Minnesota. Its commercial footprint encompasses the United States market, supported by commercial agreements and distribution partnerships aimed at advancing its thin-film electrode technology across neurosurgical and interventional procedures.
Summary of the business section of Neuroone Medical Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NEUROONE MEDICAL TECHNOLOGIES Corp
- Headquarters
- Eden Prairie, MN
- Address
- 7599 Anagram Dr 55344
- Phone
- (952) 426-1383
- Employees
- 18, Sep 30, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- September 30
- Auditor
- Baker Tilly US, LLP, Minneapolis, Minnesota
Stock & identifiers
- Ticker
- NMTC
- Exchange
- Nasdaq
- Shares outstanding
- 9M, Aug 11, 2026
- Public float
- $25.50M, Mar 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-6 reverse, May 12, 2026; 1-for-6 reverse, Apr 16, 2026; 1-for-3 reverse, May 14, 2021; 1-for-3 reverse, Apr 1, 2021
- SEC CIK
- 1500198
- CUSIP
- 64130M308
- ISIN
- US64130M3088
- EIN
- 27-0863354
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David A. Rosa | CEO & President, Director | 1,080,132 |
| David J. Wambeke | Chief Business Officer | 199,999 |
| Steve Mertens | Chief Technology Officer | 152,141 |
| Christopher Volker | Chief Financial Officer | 75,000 |
| Emily J. Johns | Chief Administrative Officer | – |
| Mark Christianson | Market Development Director | 20,692 |
| Ronald W. McClurg | Chief Financial Officer | 444,117 |
| Jason Richard Mills | Director | 49,687 |
| Paul Buckman | Director | 178,733 |
| Jeffrey S. Mathiesen | Director | 156,343 |
| Edward Andrle | Director | 133,932 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Rosa | $1.15M | $1.25M | $605.60K | $53 | – |
| FY2024 Mr.Rosa | $2.00M | $1.92M | $655.35K | $59 | – |
| FY2023 Mr.Rosa | $989.56K | $716.28K | $423.94K | $53 | – |
| FY2022 Mr.Rosa | $1.19M | $539.03K | $384.60K | $42 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of September 30, 2025, we had 18 employees,”
Corporate history
Events identified from SEC filings